PKR is activated in MDS patients and its subcellular localization depends on disease severity. (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• PKR is activated in MDS patients and its subcellular localization depends on disease severity. (Articolo in rivista) (literal)

Anno

• 2008-01-01T00:00:00+01:00 (literal)

Alternative label

• Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, Blalock WL, Cocco L, Martelli AM. (2008)
  PKR is activated in MDS patients and its subcellular localization depends on disease severity.
  in Leukemia
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, Blalock WL, Cocco L, Martelli AM. (literal)

Pagina inizio

• 2267 (literal)

Pagina fine

• 2269 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 22 (literal)

Rivista

• Leukemia (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell’Apparato Locomotore, Sezione di Anatomia, Cell Signaling Laboratory, Universita` di Bologna, Bologna, Italy; Dipartimento di Ematologia e Scienze Oncologiche ‘L e A Sera`gnoli’, Universita` di Bologna, Bologna, Italy; Hematology Unit, Ospedale Civile di Piacenza, Piacenza, Italy Istituto di Genetica Molecolare del CNR, c/o IOR, Bologna, Italy (literal)

Titolo

• PKR is activated in MDS patients and its subcellular localization depends on disease severity. (literal)

Abstract

• Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by progressive cytopenia and increased tendency of acute myeloid leukemia (AML) transformation.1 While the majority of patients are diagnosed with low-grade disease, approximately two-thirds will succumb to complications of peripheral blood cytopenia or progression into AML. That is why the phenotype of high risk MDS has often been associated with some AML features. However, a unique aspect of MDS is the notion that both bone marrow failure and the propensity towards development of AML coexist. As both properties contribute to peripheral blood cytopenia and the natural history of the disease, it is thought that proliferative advantages lend themselves more to leukemic transformation, while initially accelerated apoptosis is responsible for the cytopenia........ (literal)

Prodotto di

• Institute of molecular genetics (IGM) (Istituto)
• Bersagli molecolari per il controllo della progressione tumorale (ME.P03.012.001) (Modulo)

Autore CNR

• Alberto Maria Martelli (Unità di personale esterno)

Incoming links:

Prodotto

• Institute of molecular genetics (IGM) (Istituto)
• Bersagli molecolari per il controllo della progressione tumorale (ME.P03.012.001) (Modulo)

Autore CNR di

• Alberto Maria Martelli (Unità di personale esterno)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Leukemia (Rivista)